eVLP is a cutting-edge delivery technology that is highly scarce globally and has extremely high technical thresholds. The core difficulty lies in achieving "efficient loading, precise delivery, low immunogenicity and large-scale production" at the same time. Currently, only a few top international institutions and companies have systematic research and development capabilities. Compared with traditional AAV, eVLP represents the next generation direction in terms of structural design, assembly mechanism, delivery efficiency and safety, and is regarded as a "strategic platform technology" in the field of gene therapy. Due to complex technology, extremely high process barriers, and long verification cycles, there are only a handful of teams in the world that truly master this technology and have the ability to industrialize it, which has significant scarcity and forward-looking value. However, it has long faced industrialization bottlenecks such as production dependence on transient transfection, large batch differences, limited amplification capabilities, and high costs.

The invention patent authorized this time has systematically proposed and realized for the first time a technical path for the continuous production of engineered virus-like particles through stable cell lines. It has achieved substantial breakthroughs in terms of production consistency, amplification, quality controllability and industrialization feasibility, and has provided key support for engineering virus-like particles to move from "scientific research grade" to "clinical grade and industrial grade".

This patented technology can be widely used in multiple core application scenarios such as delivery of gene editing tools (such as CRISPR/Cas system), gene modification of cell therapies such as CAR-T/CAR-NK, in vivo and in vitro gene therapy, and delivery of new nucleic acid drugs. It has clear clinical translation value and large-scale production potential.

Relying on this core patent, Shenzhen Cell Valley is continuing to improve its engineered virus-like vectors and new gene delivery system platforms, and forming in-depth synergies with the company's existing capabilities in viral vector CDMO, cell therapy GMP production, cross-border clinical delivery, and international registration filing (DMF), to further consolidate its systemic barriers in the underlying key technical fields of cell and gene therapy.

Professor Shi Yuanyuan, chairman of Shenzhen Cell Valley, said that the successful authorization of this invention patent is an important phased achievement of the company's long-term persistence in original technology research and development and industrialization-oriented innovation. In the future, the company will continue to focus on the three major directions of cell therapy, gene therapy and advanced delivery systems, accelerate the clinical transformation and international layout of core technologies, and help China's cell and gene therapy industry achieve a critical leap from "following" to "running parallel or even leading".